The i-Lumen™ AMD device and its software are based upon the Company's proprietary technology, which is patented in the US, Australia, Canada, and the European Union. The i-Lumen™AMD device is designed to treat patients, using the company's Neural Retinal Therapy™. In ophthalmic clinical treatments, the company's patented technology will deliver a micro-current pulsed electric field in a carefully timed sequence, directed to the retina and to diseased macular tissue, by accessing ion channels that interlink the neural network of the macula of the eye, changing cell polarities and voltage gradients, and restoring functional cellular metabolism to the rod and cone cells, as well as the underlying retinal pigment epithelium.
i-Lumen Scientific's product is not yet available for treatment of AMD.
POTENTIAL VISION IMPROVEMENT PROGRESSION
VISION WITH DRY AMD
VISION IMPOVEMENT - IN PROGRESS
AFTER VISION IMPROVEMENT
To support and strengthen the company’s technology position, I-Lumen Scientific™ has filed and been granted two US patents, an Australian patent, a Canadian patent, and an EU patent. i-Lumen Scientific's technology contains proprietary hardware and software, which administers its Neural Retinal Therapy™ treatment regimen, controls dosing, and captures patient treatment data. In vivo research at Harvard Medical School’s, Schepens Eye Institute, has demonstrated an increase in neural plasticity and photoreceptor survival, using this micro-current pulsed electric field therapy, at the cellular level.